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Abstract
Background: Neisseria meningitidis diversifies rapidly, due to its high recombination rates. The aim of this study was to
analyze the possible impact of two vaccination campaigns (a once-off A/C polysaccharide vaccination campaign in people
aged 18 months to 20 years old in 1997, and a meningococcal C conjugate vaccination campaign in children aged #6 years
old from 2000 to 2008) on diversification of the population of invasive isolates obtained between 1997 and 2008. All of the
461 available isolates were included (2, 319, 123, 11 and 6 belonging to serogroups A, B, C, Y and W-135, respectively).
Methodology/Principal Findings: The isolates were analyzed for diversity using multilocus sequence typing, eBURST and
the S.T.A.R.T.2 program. One hundred and seven sequence types (ST) and 20 clonal complexes were obtained. Five different
STs (ST11, ST8, ST33, ST1163 and ST3496) included 56.4% of the isolates. With the exception of ST11, all other STs were
associated with a specific serogroup. Epidemic circulation of serogroup C ST8 isolates was detected in 1997–1998, as well as
epidemic circulation of ST11 isolates (serogroups B and C) in 2002–2004. The epidemic behavior of serogroup B ST11
(ST11_B:2a:P1.5) was similar, although with lesser intensity, to that of ST11 of serogroup C. Although clonality increased
during epidemic years, the overall diversity of the meningococcal population did not increase throughout the 12 years of
the study.
Conclusion: The overall diversity of the meningococcal population, measured by the frequency of STs and clonal
complexes, numbers of alleles, polymorphic sites, and index of association, remained relatively constant throughout the
study period, contradicting previous findings by other researchers.
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Introduction
The only natural reservoir for Neisseria meningitidis is the human
pharynx. Persons with nasopharyngeal colonization become
asymptomatic carriers. Neisseria meningitidis clones are considered
to diversify rapidly due to the high rates of recombination and
mutation of this bacterium [1]. Diversification is much lower
among isolates involved in disease episodes than in those found in
asymptomatic carriers [2], although isolates causing invasive
disease show wide variation in space and time [3]. It is generally
accepted that host immune pressure leads to antigenic diversity.
Polysaccharide vaccines are effective in controlling outbreaks
caused by meningococci of the serogroups included in the vaccine
but do not induce long-term protection, herd immunity, or
protection in children aged less than 2 years old. The recent
introduction of the meningococcal conjugate vaccine has reduced
both the incidence of meningeal disease and pharyngeal
colonization [4–6]. Despite the benefits of vaccination, other
effects such as capsule switching are a cause of concern [7,8,9]. In
addition, the decrease in meningococcal circulation and pharyn-
geal colonization after mass immunization may generate a niche
that could be occupied by other isolates, which may contribute to
an increase in diversity [10].
The aim of this study was to identify the distribution of clones
and the diversity of disease-associated isolates of Neisseria meningitidis
collected over a 12-year period in a region of northern Spain (the
Basque Country) where two mass immunization campaigns have
been carried out in the last few years.
Materials and Methods
All isolates causing invasive meningococcal disease in the
provinces of Araba, Gipuzkoa and the eastern region of Bizkaia in
the Basque Country, northern Spain, were included. A total of 461
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meningococcal disease between January 1997 and December 2008
were available for full molecular characterization. Only one isolate
per patient was included.
Capsular serogroup was identified through latex agglutination
with group-specific capsular polysaccharides of serogroups A, B,
C, W135 and Y (Murex Biotech Ltd., Dartford, England). In non-
serogroupable isolates, genogroup specific real-time polymerase
chain reaction (PCR) was performed with a LightCycler apparatus
(Roche Diagnostics Mannheim, Germany), using primers (Tib
Molbiol, Berlin, Germany) specific for the siaD and orfA genes [11].
The genosubtype was determined as previously described [12]
through amplification of two fragments of the porA gene coding for
VR1 and VR2, sequencing, and subsequent comparison of the
deduced amino acid sequence with PorA types available at the
N. meningitidis PorA variable region database (http://neisseria.org/
nm/typing/pora/).
Multilocus sequence typing (MLST) was performed by
amplification and sequencing of seven housekeeping genes [13].
Briefly, a suspension containing approximately 10
6 cells was
incubated with 0.1 mg/mL proteinase K. Genomic DNA was
extracted from all isolates with a QIAamp DNA Blood Mini kit
(QIAGEN, Hilden, Germany). PCRs were carried out with 50 mL
amplification mixtures using 5–50 mg of template DNA in a
thermal cycler (Applied Biosystems, Foster City, CA, USA). The
seven amplicons obtained were sequenced (forward strand or
forward and reverse when the analyzed sequence did not match
the reference sequences) in an ABI PRISM 3100 Genetic Analyzer
(Applied Biosystem, Foster City, CA, USA). Primers, determina-
tion of sequence alleles, and designation of sequence types (ST) are
described on the MLST web site (http://neisseria.org/nm/
typing/mlst/). The clonal complexes reported were those
contained in the PubMLST database of the above-mentioned
MLST website.
Pulsed-field gel electrophoresis (PFGE) was performed ac-
cording to previously described standard protocols [14] using
SpeI restriction endonuclease (Amersham Pharmacia Biotech,
Buckinghamshire, England). PFGE patterns were analyzed with
the Diversity Database Fingerprinting software version 2
(BioRad, Hercules, USA) and a dendrogram was constructed
by the unweighted pair group method with arithmetic averages,
the Dice coefficient, and a position tolerance of 1%. Isolates with
a PFGE pattern similarity of $85% were considered to represent
ac l o n e .
Diversity Analysis
eBURST is a tool that allows STs to be classified into distinct
groups or lineages according to their similarity in allelic profiles.
Every ST within an eBURST group has a minimum number of
identical alleles in common with at least one other ST in the
group. In this study, the eBURST analysis was performed with the
stringent (default) group definition of six out of seven shared
alleles, as described at http://eburst.mlst.net/. Use of this criterion
(6/7 shared alleles) ensures that the isolates classified within a
group belong to the same clonal complex.
Intra- and intergroup comparisons were made using the
Sequence Type Analysis and Recombinational Tests (S.T.A.R.T.2)
[15] suite of programmes available at http://pubmlst.org/soft-
ware/analysis/start2/. The S.T.A.R.T. programme allows group
assignment to be performed in bacterial populations and recombi-
nation and selection phenomena to be analyzed using multilocus
sequence data.
The parameters used to measure diversity over the study years
were as follows: serogroup frequencies, STs and clonal complexes
and their respective ratios with respect to the number of isolates,
the number of alleles present at each locus, the number of
polymorphic sites at each locus (positions at which variation was
observed) and their respective ratios with respect to the number of
isolates. Finally the index of association (IA) was calculated. This
test allows the degree of recombination within a population to be
quantified through the formula: IA=Vo/Ve-1 (where Vo is the
variation observed in the number of loci in which two individuals
differ and Ve is the expected variation). IA=0 indicates frequent
recombination events and IA.0 indicates increasing clonality due
to a lack of recombination events.
The phenotypic and genotypic characteristics of isolates
representing each of the STs reported in this study were deposited
in the PubMLST Database (http://pubmlst.org/neisseria/).
Immunization Campaigns
Two mass immunization campaigns were carried out in the
Basque Country in the last 12 years (1997–2008). The first was a
once-off campaign in October 1997, using the bivalent A/C
meningococcal polysaccharide vaccine (MencevaxH,G S K ,T r e s
Cantos-Madrid, Spain). The target population consisted of
414,888 persons aged 18 months to 20 years with an overall
coverage of 88.6% (99% in children and teenagers aged 6–17
years and 58% in 18–20-year-olds). Three years later, in
October 2000, the monovalent meningococcal serogroup C
conjugate vaccine (MCVc) (MeningitecH, Wyeth Farma, San
Sebastian de los Reyes-Madrid, Spain) was introduced in the
Basque Country. This late vaccination campaign introduced a
routine three-dose infant vaccination series and included a mass
catch-up, A total of 78.2% of the children born in 2000 received
the three vaccine doses. The catch-up was made in 2000 in
children aged from 12 months to 6 years, with a coverage of
95%. More than 94% of children born since 2001 have received
three vaccine doses.
To calculate the incidence rates of invasive meningococcal
disease by age groups, official data from the population living in
the study areas (Eustat, Basque Institute office; http://www.eustat.
es) were used. Census data were available for 1996, 2001 and
2006, while the values for the remaining years were estimated.
Epidemic years are defined as those in which the incidence of
meningococal disease increased due to the predominance of a
single ST
Statistical Analysis
The Chi square test for trends was used to compare the annual
incidence rate. To analyze differences in clonality, ratios were
compared (Crame ´r-von Mises) with calculation of P-values
through permutations (10,000 random permutations).
Ethics Statement
The creation of the ‘‘Meningococcal Infection Reference
Laboratory’’ in the 90s had its justification in the possibility of
analyzing the phenotype and genotype of strains causing invasive
infections in our region, to gain knowledge about the epidemiology
of the disease. In the present study no human experimentation was
conducted, with all studies carried out on microorganisms. The
data referred to are associated with meningococcal strains, with no
patient information used other than age, gender and vaccination
status. Publication of the results obtained by this Reference
Laboratory concerning the phenotype and genotype of the strains
studied and their relation to age, gender and vaccination status of
the patients was approved by the ‘Comite ´E ´tico de Investigacio ´n
Clı ´nica del A ´rea Sanitaria de Gipuzkoa’.
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Of the 497 microbiologically-confirmed cases of invasive
meningococcal disease in the study area, 349 (70.2%) were caused
by serogroup B meningococci, 129 (26%) by serogroup C (Table 1),
11 (2.2%) by serogroup Y, 6 (1.2%) by serogroup W-135, and 2
(0.4%) by serogroup A. The mean annual number of cases was 41
(range 23–59), giving a mean annual incidence of 3.66100,000
inhabitants. In 461 (92.8%) of these 497 episodes, the strain for
molecular study of diversity was available (Table 2). After the
introduction of the MenC conjugate vaccine (in October 2000),
224 episodes caused by serogroup B and 72 by serogroup C were
detected, of which 93 (41.5%) and 11 (15.3%), respectively,
occurred in children eligible for vaccination, four of whom were
previously vaccinated.
MLST analysis of the isolates showed 107 different STs. Of
these, 54 were new STs, not previously been described in the
PubMLST Database (http://pubmlst.org/neisseria/submission.
shtml). The distribution of isolates by ST showed wide
heterogeneity. The predominant ST was ST11, representing
23% (106/461) of the isolates, and more than half of the isolates
(260/461, 56.4%) were included in five STs: ST11, ST8 (51
isolates), ST33 (47 isolates), ST1163 (37 isolates), and ST3496 (19
isolates). In contrast, 77 isolates each represented a distinct ST (77
STs with a single isolate). The number of STs detected each year
ranged from 11 (1997 and 2007) to 29 (2003) (Table 2). The ratio
between the number of isolates and the number of STs was not
constant over time, being significantly lower in some years than
others (P,0.001). However, this ratio showed no upward or
downward trend over the twelve years of study.
There was a strong association between ST and serogroup. All
ST32, ST33 and ST1163 isolates expressed serogroup B, while 50
ofthe51ST8 isolatesexpressedserogroup C.Exceptforthree ST23
isolates (one each from serogroups B, C and Y), and ST11 (reported
in greater detail below), the remainder included only or mainly
(.85%) isolates from a single serogroup: ST22 (serogroup W135),
ST1768 (serogroup Y), and the remaining STs (serogroup B).
The 319 serogroup B isolates were grouped into 94 STs, while
the 123 serogroup C isolates belonged to only 12 different STs
(Table 3). Isolates expressing serogroup B showed higher ST
diversity (ratio 3.4) than those expressing serogroup C (ratio 10.3)
(P,0.001). ST diversity was obtained by applying the ratio
between the number of isolates and the number of STs; the lower
the value of the ratio, the greater the diversity.
Using the Neisseria PubMLST Database, 431/461 (93.5%)
isolates and 89/107 (83.2%) STs detected in the Basque Country
were assigned to one of the clonal complexes available in this
database. In total, isolates belonging to 20 distinct clonal
complexes were identified, the most numerous being the following:
ST11/ET-37 complex (113 isolates), ST32/ET-5 complex (79
isolates), ST8/Cluster A4 (56 isolates), ST269 complex (49
isolates), ST41/44 Lineage 3 (38 isolates) and ST461 complex
(27 isolates). These top six clonal complexes make up 78% of all
the isolates.
Using eBURST, 71 STs (411 isolates) of the 107 STs identified
in our region were classified into groups, with the remaining 36
being unrelated or singleton STs (50 isolates) (Table 4). Two of the
groups identified could not be included in any of the clonal
complexes defined to date (groups 3 and 5). Likewise, 24 singleton
STs are described for the first time in this study. The number of
STs in each group ranged from 2 to 11 (median 5) and the number
of isolates from 2 to 111 (median 10). Group 3 was composed of 10
isolates, all serogroup B, belonging to four distinct STs (ST4954,
ST6423, ST6424, ST6651), and group 5 by 9 isolates (5 serogroup
Y, 3 serogroup B, 1 serogroup C) belonging to 5 STs (ST1768,
ST2196, ST6407, ST6411, ST6432).
Intra- and intergroup diversity analyzed with the S.T.A.R.T.2
programme showed that the allele frequency at each locus for each
Table 1. Number of cases and incidence rate (in brackets) of invasive Neisseria meningitidis of serogroup B and C by groups of age
in the Basque Country, north of Spain (1997–2008).
,1 year 1–6 years 7–12 years 13–18 years .18 years Total
BC BCB C B C B C B C
1997 0
a (0.0)
b 3 (34.6) 4 (7.4) 12 (22.1) 1 (1.4) 5 (6.9) 1 (1.0) 4 (3.9) 6 (0.6) 5 (0.5) 13 (1.1) 28 (2.3)
1998 2 (23.1) 0 (0) 18 (33.1) 5 (9.2) 4 (5.5) 1 (1.4) 0 (0) 1 (1.0) 8 (0.8) 5 (0.5) 32 (2.7) 12 (1.0)
1999 4 (46.2) 0 (0) 12 (22.1) 1 (1.8) 3 (4.2) 0 (0) 2 (2.0) 0 (0) 10 (1.0) 1 (0.1) 31 (2.6) 2 (0.2)
2000 7 (80.8) 2 (23.1) 16 (29.4) 8 (14.7) 1 (1.4) 0 (0) 1 (1.0) 0 (0) 4 (0.4) 5 (0.5) 29 (2.4) 15 (1.3)
2001 3 (34.6) 1 (11.5) 9 (16.6) 0 (0) 2 (2.8) 1 (1.4) 3 (3.0) 2 (2.0) 11 (1.2) 3 (0.3) 28 (2.3) 7 (0.6)
2002 4 (46.2) 0 (0) 5 (9.2) 4 (7.4) 1 (1.4) 3 (4.2) 6 (5.9) 3 (3.0) 15 (1.6) 18 (1.9) 31 (2.6) 28 (2.3)
2003 4 (46.2) 0 (0) 13 (23.9) 2 (3.7) 2 (2.8) 1 (1.4) 8 (7.9) 4 (3.9) 12 (1.3) 8 (0.8) 39 (3.3) 15 (1.3)
2004 2 (26.3) 0 (0) 6 (12.6) 1 (2.1) 3 (4.7) 0 (0) 6 (6.7) 6 (6.7) 15 (1.8) 3 (0.4) 32 (3.1) 10 (1.0)
2005 3 (39.4) 0 (0) 14 (29.3) 0 (0) 4 (6.3) 0 (0) 6 (6.7) 1 (1.1) 10 (1.2) 3 (0.4) 37 (3.5) 4 (0.4)
2006 5 (65.7) 0 (0) 7 (14.7) 0 (0) 2 (3.2) 0 (0) 3 (3.4) 0 (0) 11 (1.3) 2 (0.2) 28 (2.7) 2 (0.2)
2007 5 (65.7) 0 (0) 14 (29.3) 1 (2.1) 1 (1.6) 0 (0) 3 (3.4) 0 (0) 7 (0.8) 1 (0.1) 30 (2.9) 2 (0.2)
2008 4 (52.5) 0 (0) 3 (6.3) 1 (2.1) 2 (3.2) 0 (0) 2 (2.2) 1 (1.1) 8 (1.0) 2 (0.2) 19 (1.7) 4 (0.4)
Total 43 (43.6) 6 (6.1) 121 (19.5) 35 (5.7) 26 (3.2) 11 (1.3) 41 (3.6) 22 (1.9) 117 (1.1) 56 (0.5) 349 (2.6) 129 (0.9)
X
2 for trend 0.3 6.8 1.2 25.3 0.2 8.1 1.9 0.2 1.9 2.7 0 21.9
P value NS 0.009 NS ,0.001 NS 0.004 NS NS NS NS NS ,0.001
anumber of cases.
bincidence per 100,000 inhabitants.
NS: Difference not significant.
doi:10.1371/journal.pone.0008501.t001
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and 2007) to 15 for aroE and pgm in 2003. The number of
polymorphic sitespresentat each locus rangedfrom 9 for adk(1999,
2000, 2001, 2003, 2006 and 2007) to 164 for aroE in 2000. Table 2
shows the annual mean and the ratio between each of the above-
mentioned parameters and the number of isolates, as well as the IA.
The circulation of ST11 isolates deserves special mention since,
of the 106 isolates of this ST, 43 expressed serogroup B and 63
expressed serogroup C capsules, all showing a similarity of .85%
when analyzed by PFGE. Serotyping and porA VR typing
revealed that all strains showed the 2a:P.1.5 phenotype with
variations in VR2 except for one serogroup B strain, which,
instead of serotype 2a, showed serotype 4.
Complementary analysis of the fum gene allowed the 106 ST11
isolates to be classified within the ET15 variant of the ST11/ET37
clonal complex. The number of ST11 strains isolated each year
and their corresponding serogroup are shown in Figure 1.
During the study period, epidemic circulation of serogroup C
ST8 isolates was detected in 1997–1998 and preferential
circulation of ST11 isolates (serogroups B and C) was found in
2002–2004. Figure 2 indicates how clonality increased during
epidemic years and how the diversity of the invasive meningo-
coccal population in our region did not increase throughout the 12
years of the study.
Discussion
Phenotypic and genotypic analysis was performed in all of the
461 available invasive meningococci isolates collected from the
study area. These isolates came from a well delimited area in
which active follow-up was performed of the episodes occurring in
12 consecutive years, 8 of these after vaccination with the
meningococcal C conjugate vaccine was implemented in the
population aged less than 7 years.
Despite the high capacity for genetic recombination shown by
N. meningitidis, some disease-causing meningococcal clones or
groups of related clones (clonal complexes) circulate practically
unaltered all over the world for very prolonged periods. In the
present study, circulation of invasive isolates belonging to more
than 100 distinct STs was detected, although more than half of the
isolates were grouped in only five STs, corresponding to the
following clonal complexes: ST11/ET-37 complex, ST32/ET-5
complex, ST8 complex/Cluster A4, ST269 complex, and ST213
complex. This epidemiological situation is broadly similar to that
in other areas of Europe and the developed world, both in
countries that have included the conjugate vaccine in their
immunization schedules and those that have not [16–20]. The
data for 1999–2006 collected in 18 European countries through
the EU-MenNet Project also showed wide variation in the STs
among the invasive isolates analyzed, the predominant clonal
complexes coinciding with those detected in our region [16].
The overall incidence of meningococcal disease showed no
significant variation in tendency throughout the 12 years of the
study, nor was significant variation observed in the incidence of
disease caused by serogroup B meningococci. However, the
incidence of disease caused by serogroup C N. meningitidis showed a
decreasing tendency in children aged less than 12 years
throughout the study period. Serogroup C caused 27% of the
episodes, peaking in 2002 when this serogroup caused 45% (27/
60) of the episodes, even though immunization in children aged
less than 7 years old had been introduced 2 years previously and a
vaccination coverage of $90% had been achieved in this age
group. Most serogroup C cases in 2002 (18/27) occurred in adults
.19 years old. Among the remaining 9 patients, only one 4-year-
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countries have reported a dramatic reduction in the incidence of
meningococcal disease due to serogroup C isolates after the
introduction of the conjugate vaccine in both vaccinated and non-
vaccinated individuals [4,5,17]. In our region, vaccination
achieved optimal protection among vaccinated individuals but
did not curtail circulation of serogroup C isolates among non-
vaccinated persons, especially in 2000 and 2003, when the ST11/
ET37 complex circulated widely, as in other countries such as
France, Iceland and the Czech Republic [16,17,19]. Comparison
of the incidence of invasive diseases in children less than 7 years
old in the study region between the prevaccination -conjugate
vaccine- period (1997–1999) and the postvaccination period
(2001–2008), revealed a highly significant reduction, due to a
marked decrease in serogroup C cases (incidence rate 11.1 vs. 2.0
cases6100,000 inhabitants, respectively; P,0.001). Nevertheless,
no differences in incidence were observed between the two periods
for serogroup B cases in children aged less than 7 years old, or in
any other age group.
In the Basque Country in 1997, a once-off vaccination
campaign was performed with the polysaccharide vaccine in 18
months to 20-year-olds, achieving coverage of 88.6%. This
polysaccharide vaccine and/or the subsequent conjugate vaccine
could have had some effect on the circulation of ST11_B:2a:P1.5
isolates in the ensuing years. After 2001 meningococci of the ET15
variant of the ST11/ET37 complex, belonging to serogroup B,
were increasingly isolated, matching the prevalence of serogroup
C isolates of this clonal complex, which were already circulating.
Strains of this ET15 variant circulated throughout the world,
especially after 1990, causing major outbreaks [16–20]. The
increase observed in the number of ST11_B:2a:P1.5 isolates was
initially interpreted as capsule switching phenomenon, arising
from the initial presence of ST11_C:2a:P1.5 [8]. Nevertheless,
independently of whether the capsule switching phenomenon was
stimulated or not by vaccination, the number of ST11_B:2a:P1.5
isolates initially increased and later decreased. This epidemic
behavior was similar, although with lesser intensity, to that of the
most typical isolates of ST11 of serogroup C.
The increase and subsequent decrease in the number of cases of
both serogroups (Figure 1), as well as their superposition (serogroup
B plus serogroup C), reflects the epidemic dissemination of the
hypervirulent ST11 inan only partially immunized population. The
Table 3. Distribution by clonal complex, sequence type and PorA type of 319 serogroup B and 123 serogroup C invasive
meningococci from the Basque Country, north of Spain (1997–2008).
Serogroup
ST clonal complex
(No isolates) Sequencetype (ST), PorA type (P) (No isolates)
C ST11/ET-37 complex (64) ST11, P5-10 (58); ST11, P5-2 (4); ST11, P5-14 (1); ST3419, P5-10 (1)
C ST8/Cluster A4 (55) ST8, P5-2 (49); ST8, P5-12 (1);ST66, P5-2 (1); ST3331, P5-2 (1); ST6414, P5-2 (1); ST6420, P5-2 (1); ST6645, P5-2 (1)
C ST461 complex (1) ST461, P5-2 (1)
C ST213 complex (1) ST3496, P22-14 (1)
C ST23 complex/ClusterA3 (1) ST23, P5-10 (1)
C Not clonal complex (1) ST6411, P21-4 (1)
B ST32/ET-5 complex (78) ST33, P5-2 (23); ST33, P19-15 (19); ST33, P7-4 (2); ST33, P18-3 (1); ST33, P19-2 (1); ST749, P19-15 (12);
ST749, P5-15 (1); ST749, P21-15 (1); ST32, P7-16 (2)
ST32, P7-4 (1); ST32, P19-15 (1); ST32, P19-16 (1); ST32, P17-13 (1); ST34, P19-15 (4); ST343, P7-16 (1); ST639, P7-16 (1);
ST5101, P19-15 (1); ST5682, P19-15 (1); ST6435, P13-12 (1); ST6640, P7-4 (1); ST6647, P5-2 (1); ST6979, P19-15 (1)
B ST11/ET-37 complex (49) ST11, P5-10 (42); ST11, P5-2 (1); ST6648, P12 (2); ST3419, P5-10 (1); ST3419, P7-30 (1); ST4091, P5-10 (1); ST4706,
P5-10 (1)
B ST269 complex (n=49) ST1163, P22-9 (33); ST1163, P22-14 (1); ST1163, P22-4 (1); ST1163, P7-30 (1); ST1163, P19-14 (1); ST269, P15-9 (1);
ST5329, P21-16 (1); ST6409, P22-9 (1); ST6410, P5-10 (1); ST6416, P22-9 (1); ST6418, P22-9 (1); ST6422, P5-2 (1);
ST6426, P22-9 (1); ST6428, P22-9 (1); ST6436, P22-9 (1); ST6637, P19-15 (1); ST6642, P14 (1)
B ST41/44 Lineage 3(38) ST41, P7-4 (10); ST3752, P22-9 (6); ST3752, P7-30 (1); ST1947, P7-14 (4); ST409, P18-34 (2); ST6408, P18-10 (1);
ST6408, P18-34 (1); ST44, P7-4 (1); ST571, P7-4 (1); ST1465, P12-9 (1); ST2820, P15-9 (1); ST3935, P5,2 (1); ST6075, P18-
34 (1); ST6406, P18-25 (1); ST6413, P12-9 (1); ST6417, P7-4 (1); ST6429, P22-14 (1); ST6641, P12-9 (1); ST6646, P7-14
(1); ST6649, P18-9 (1);
B ST461 complex (26) ST461, P19-13 (9); ST461, P19-15 (2); ST461, P17-9 (1); ST461, P17-16 (1); ST461, P18-30 (1); ST1946, P19-13 (3);
ST3494, P19-13 (2); ST6044, P,19-13 (2); ST2299, P19-13 (1); ST6415, P19-13 (1); ST6430, P19-13 (1); ST6431, P17-9 (1);
ST6639, P5-2 (1)
B ST213 complex (23) ST3496, P22-14 (17); ST3496, P5-10 (1); ST7309, P22-14 (2); ST213, P22-14 (1); ST3113, P22-14 (1); ST7307, P22-14 (1)
B ST162 complex (13) ST162, P7-4 (11); ST6980, P7-4 (1); ST7308, P7-4 (1)
B ST35 complex (11) ST35, P22-14 (7); ST457, P22-14 (1); ST807, P22-14 (1); ST4418, P22-14 (1); ST6978, P22-14 (1)
B Other clonal complex (11): ST865
complex (3); ST60 complex (1);
ST8/Cluster A4 (1); ST 22 complex (1);
ST 23 complex (1); ST 103 complex
(1); ST 116 complex (1); ST 254
complex (1); ST 364 complex (1)
ST1306, P21 (1); ST4237, P21-16 (1); ST6644, P4 (1); ST60, P5-2 (1); ST8, P5-2 (1); ST22, P18-3 (1); ST23, P5-10 (1);
ST6638, P7-4 (1); ST6643, P19-13 (1); ST6433, P22-14 (1); ST3216, P14 (1)
B Not clonal complex (21) ST4954, P19-15 (5); ST4954, P19-13 (1); ST6412, P5-2 (2); ST6412, P5-10 (1); ST6424, P19-15 (2); ST6421, P19-15 (1);
ST6423, P19-15 (1); ST6651, P19-15 (1); ST1768, P22-14 (1); ST2196, P21-14 (1); ST6432, P22-14 (1); ST1572, P7-14 (1);
ST6434, P7-14 (1); ST6977, P7-14 (1); ST7306, P19-15 (1)
Bold type indicates sequence types represented by 10 or more isolates.
doi:10.1371/journal.pone.0008501.t003
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meningococcal C conjugate vaccine was broadened to include
persons up to 19 years old, reduced the incidence and pharyngeal
colonization of serogroup C in general and that of ST11 in
particular, with an almost complete absence of serogroup B ST11
isolates being observed [5]. Nevertheless, serogroup B ST11 has
circulated with a certain frequency in Europe in the last few years.
In the EU-IBIS database for 1999–2006, the ST11 complex/ET-37
complex represented 61.8% of the total number of serogroup C
strains and 1.83% of serogroup B strains [17].
Using eBURST, 71 of the 107 STs identified in our region were
classified in one group or lineage, with the remaining 36 STs being
Table 4. eBURST analysis of 461 invasive meningococci from the Basque Country, north of Spain (1997–2008).
eBURST (No
isolates) STs
1 Clonal Complex Representative Phenotype
2
Group 1 (n=47) 1163(37); 269(1); 6409
3(1); 6416(1); 6418(1); 6422(1); 6426(1);
6428(1); 6436(1); 6637(1); 6642(1)
ST269 complex B:NT
4:9
Group 2 (n=28) 41(10); 3752(7); 6408(2); 409(2); 44(1); 571(1); 2820(1); 6075(1); 6406(1);
6429(1); 6649(1)
ST41/44 complex/Lineage 3 B:4:14
Group 3 (n=10) 4954(6); 6424(2); 6423(1); 6651(1) Non-defined B:1:15
Group 4 (n=76) 33(47); 749(14); 32(6); 34(4); 343(1); 639(1); 5101(1); 5682(1); 6647(1) ST32/ET-5 complex B:4:15
Group 5 (n=9) 1768(4); 6407(2); 2196(1); 6411(1); 6432(1) Non-defined Y:15:4
Group 6 (n=25) 461(15); 1946(3); 3494(2); 6044(2); 2299(1); 6430(1); 6431(1) ST461 complex B:1:NT
Group 7 (n=56) 8(51); 66(1); 3331(1); 6414(1); 6420(1); 6645(1) ST8 complex/ClusterA4 C:2b:5,2
Group 8 (n=24) 3496(19); 213(1); 3113(1); 7309(2); 7307(1) ST213 complex B:1:14
Group 9 (n=111) 11(106); 3419(3); 4091(1); 4706(1) ST11/ET-37 complex C:2a:5/B:2a:5
Group 10 (n=2) 1306(1); 6644(1) ST865 complex -
Group 11 (n=10) 35(7); 457(1); 807(1); 4418(1) ST35 complex B:4:14
Group 12 (n=13) 162(11); 6980(1); 7308(1) ST162 complex B:NT:4
Singletons (n=50) 22(7); 1947(4); 23(3); 6412(3); 6648(2); 60(1); 1465(1); 1572(1); 2394(1);
3216(1); 3544(1); 393(1); 4237(1); 5329(1); 6410(1); 6413(1); 6415(1);
6417(1); 6419(1); 6421(1); 6425(1); 6427(1); 6433(1); 6434(1);
6435(1); 6638(1); 6639(1); 6640(1); 6641(1); 6643(1); 6646(1);
6650(1); 6977(1); 6978(1); 6979(1); 7306(1)
--
1ST: Sequence types in order of frequency (the number of isolates is given in brackets).
2The representative phenotype was the phenotype expressed by most (.50%) of the strains in the group.
3In bold the new groups and singletons described in this article.
4NT: Non-typable.
doi:10.1371/journal.pone.0008501.t004
Figure 1. Annual distribution of serogroup ET15 variant of the ST11/ET37 complex. Annual distribution of serogroup B (n=43) and C
isolates (n=63) belonging to the ET15 variant of the ET37 complex showing multilocus sequence type 11.
doi:10.1371/journal.pone.0008501.g001
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one of the known clonal complexes,although with the stringent group
definition of six of seven shared alleles their clonal relationship could
not be established with this system. Despite its greater discriminatory
power, eBURST allowed new clonal relationships to be identified,
and two hitherto unidentified groups were established. Both groups
were composed mainly (6/9) of STs described for the first time in this
study. The number of alleles and the number of polymorphic sites at
each locus provide complementaryinformation on the diversity of the
meningococcal population analyzed, allowing detection of the
intracomplex or intragroup variation, which cannot be observed
with isolated analysis of STs and clonal complexes.
The reduction in meningococcal circulation and pharyngeal
colonization has been suggested to produce a niche that could be
occupied by other isolates, possibly contributing to the diversity
and expansion of new emerging clones [9]. A significant increase
in the genetic diversity of invasive isolates using MLST and
S.T.A.R.T. analysis was observed in a study performed in
Scotland between 1999 and 2002 [10]. We found that the
epidemic circulation of serogroup C ST8 isolates in 1997–1998
and ST11 isolates (serogroups B and C) in 2002–2004 increased
clonality in these epidemic years. Nevertheless, the parameters
used in this study show that the diversity of the population of
invasive meningococci in our region did not increase from 1997–
2008. In the present study, we identified 54 new STs, although
these STs appeared continuously over time.
Despite two vaccination campaigns, the diversity of the
population of invasive meningococci in the Basque Country
remained fairly constant over time, with few changes in
recombination phenomena, as shown by the IA obtained over
the 12 years, and the meningococcal population was always
structured in stable clonal complexes.
Identification of new STs, the use of more precise tools for
their classification, such as eBURST, and recognition of hitherto
unidentified groups has great epidemiological value to analyze
the evolution of the meningococcal population, not only in a
discrete geographical region but also globally. The methods used
for typing and classifying the population of meningococci
analyzed in the present study were complementary. The
combination of techniques with low and high discriminatory
power allowed us to determine the evolution of the invasive
meningococcal population over time, analyze its phenotypic and
genotypic diversity, and the degree of genetic recombination
among strains
In conclusion, the population of invasive meningococci in the
Basque Country is basically similar to that in other European areas
but shows certain regional distinguishing features. Vaccination in
this region practically eliminated episodes of meningococcal C
disease in vaccinated individuals but did not contain the activity of
isolates of this serogroup in the non-vaccinated population and
had little effect on the diversity of the invasive meningococcal
population in the area.
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